Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS

• Status: Completed
• Trial end date: 2017-10-20
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to learn about the pharmacokinetics and pharmacodynamics of RPC1063 in RMS.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Celgene
• Treatments: Ozanimod

Criteria

Key Inclusion Criteria:

• MS, as diagnosed by the revised 2010 McDonald criteria

• Exhibits a relapsing clinical course consistent with RMS and history of brain MRI lesions consistent with MS

• Expanded disability status scale (EDSS) score between 0 and 6.0

Key Exclusion Criteria:

• Primary progressive MS

• Clinically relevant cardiovascular conditions or other relevant diseases that could impact the implementation or interpretation of the trial, or put the patient at risk